Rosemont to Buy Aytu BioPharma for $2.70 a Share in All-Cash Tender Offer
AYTU is trading near its 52-week low of $1.75 (4.0% above the low).
Summary
Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma for $2.70 a share in cash, a 51.7% premium to the November 13 close and 41.1% above the 30-day volume-weighted average price. The deal is structured as a tender offer for all outstanding shares followed by a second-step merger at the same price, requiring a majority of shares to be tendered plus exercise or termination of certain outstanding warrants. Aytu's board unanimously approved the transaction, and support agreements are in place from Nantahala Capital Management, Stonepine Capital Management, and Aytu's directors and officers. Rosemont intends to launch the tender offer and file a Schedule TO within 10 business days, with Aytu filing a Schedule 14D-9 concurrently. Closing is anticipated in late December 2026, subject to tender conditions.
At the time of this announcement, AYTU was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $1.75 to $3.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: ACCESS Newswire.